Sutherlandia.Org - An information and links site for Sutherlandia frutescens

Information and links on Sutherlandia frutescens

   
Site Links
Home Page
Chemistry and Pharmacology
Current Uses
Safety of Sutherlandia
Sutherlandia and HIV/AIDS
Sutherlandia and Cancer
Chronic Fatigues Syndrome
Diabetes and Sutherlandia
Sutherlandia as Antioxident
Sutherlandia and Canavanine
Questions and Answers
Published Literature
Sources - Best places to buy
Contact Us
Links Page

 


Sutherlandia and AIDS Patients - Summary of a field trip in South Africa... more...


Sutherlandia in the news:

- IOL (RSA)
- Business Day (RSA)
- IOL (RSA)
- NewScientist.Com
- BBC news (UK)
- Independent News (UK)
- The Cape Argus (RSA)
- The Sunday Times (RSA)
- The Daily Dispatch (RSA)
- Remarks by the chairman of
  The House of Traditional
  Leaders

I have a patient with leukemia whose blood values and symptoms have been better than ever corresponding to her initiation of Sutherlandia over the last 3 years!
Dr LS - Washington, USA

Thesis: The influence of Sutherlandia frutescens on adrenalcytochrome P450 11ß-hydroxylase by Catherine Anne Sergeant

 

Sutherlandia and Cancer


Sutherlandia frutescensThis brief document is intended to answer the frequent questions asked about the use of Sutherlandia tablets/capsules in patients with cancer. There is a well-established present and historical folk-use of Sutherlandia in the treatment of cancers, and indeed the Afrikaans name is Kankerbos, or Cancer Bush in English. This has created expectations from patients, friends and relatives which should be tempered by responsible information.

Quality-of-Life Tonic
There is preliminary clinical evidence that Sutherlandia has a direct anticancer effect in some cancers, and also acts as an immune stimulant, but Sutherlandia should not be recommended as a so-called “universal cancer cure”, but rather as a quality-of-life tonic.

  • Mood
    Sutherlandia decreases anxiety and irritability and it elevates mood.
  • Appetite and weight
    It is an established fact that up to a third of cancer patients succumb to the wasting syndrome, rather than the actual tumor mass. Appropriate doses of select chemotypes and varieties of Sutherlandia dramatically improves appetite, and weight-gain can be expected in wasted patients. The first 5 kg gain is common after six weeks of treatment. In patients who are not wasted, weight-gain is not usual.
  • Energy levels and exercise tolerance
    Sutherlandia typically improves the energy levels and exercise tolerance of patients, and gives an enhanced sense of well-being.

Qualified Healthcare Professionals
It is recommended that all cancer patients get assessed and managed by an appropriately qualified healthcare professional with recognized experience in managing cancer. The patient will need to make an informed decision about the treatment modalities to follow in his / her specific case. A decision should be made on whether or not Sutherlandia and / or other natural approaches to managing cancer should be included, and if so at what stage of the planned treatment regimen.

Nutrition
It is recommended that any cancer management programme should include meticulous attention to optimizing diet in consultation with a professional nutritionist with experience and interest in cancer.

Emotional, Cultural and Spiritual
The participation of a psychologist, traditional healer and / or spiritual person could also be considered as part of the holistic team to provide support for the important but neglected emotional, cultural and spiritual aspects of the illness.

Dose of Sutherlandia
The minimum dose of select Sutherlandia varieties for enhanced quality-of-life is one tablet (300 mg) twice a day, after meals. This can be taken long-term.

Many cancer patients, in an effort to explore possible anticancer activity, choose to self-medicate with two tablets (600 mg) three times a day after meals. This is typically taken long term.

Precautions
It is not recommend that Sutherlandia be taken during pregnancy.


Publications:
A number of recent published scientific studies on Sutherlandia have shown interesting results, including anti-HIV activity, anti-oxidant activity, anti-inflammatory activity, anti-cancer activity, and also potential drug interaction between Sutherlandia and anti-retroviral drugs. Summaries of the published studies are included. People living with HIV should discuss the potential use of Sutherlandia with their doctor or healthcare professional.

J Ethnopharmacol. 2005 Jan 4;96(1-2):113-9.

Anti-HIV activities of organic and aqueous extracts of Sutherlandia frutescens and Lobostemon trigonus.
Harnett SM, Oosthuizen V, van de Venter M.


Department of Biochemistry and Microbiology, University of Port Elizabeth, PO Box 1600, Port Elizabeth, 6000 South Africa.

A screening process was applied to extracts made from Sutherlandia frutescens (L.) R. Br (Fabaceae) and Lobostemon trigonus (Boraginaceae) as identified by the Botany Department, University of Port Elizabeth to detect if any of the extracts inhibited the human immunodeficiency virus (HIV). For purposes of dereplication, sulphated polysaccharides were removed and bovine serum albumin (BSA) was included in the assays to adsorb non-specific tannins potentially present. In the reverse transcriptase (RT) assay, an aqueous extract of the Lobostemon leaves inhibited HIV-1 RT with an IC50 value of 49 microg/ml, while in the protease assay no inhibition was seen. In the alpha- and beta-glucosidase assays, no significant inhibition was seen with the inclusion of BSA, indicating tannin-based inhibitory effects on these two enzymes. The beta-glucuronidase inhibitory activity, however, was retained in the presence of BSA. The study shows that Sutherlandia extracts contain inhibitory compounds active against HIV target enzymes, while aqueous Lobostemon leaf extracts contain a potent HIV-1 RT inhibitor, thus showing a potential mechanistic action of these plants in aiding HIV-positive patients.


J Ethnopharmacol. 2004 Nov;95(1):1-5.

The antioxidant potential of Sutherlandia frutescens.
Fernandes AC, Cromarty AD, Albrecht C, van Rensburg CE.

Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, PO Box 2034, Pretoria 0001, South Africa.

One of the best-known multi-purpose medicinal plants in Southern Africa, Sutherlandia frutescens subsp. microphylla (family: Fabaceae/Leguminosa), is used for a wide range of conditions, including cancer, viral diseases and inflammatory conditions. Little scientific data has been documented on the mechanism by which Sutherlandia frutescens acts on the immune system. Phagocyte derived reactive oxygen species, such as hydrogen peroxide and superoxide radicals, are responsible for the pathogenesis of various inflammatory conditions. Anti-inflammatory properties of various medicinal-plant extracts have been explained, at least in part, by their antioxidant activities. We investigated the effects of a hot water extract of Sutherlandia frutescens on both luminol and lucigenin enhanced chemiluminescence of neutrophils stimulated with L-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) as well as its superoxide and hydrogen peroxide scavenging properties in a cell free system. The results indicate that Sutherlandia frutescens extract possesses superoxide as well as hydrogen peroxide scavenging activities at concentrations as low as 10 microg/ml, which could account for some of the anti-inflammatory properties that have been described.


Methods Find Exp Clin Pharmacol. 2004 Jul-Aug;26(6):409-16.

Analgesic, antiinflammatory and hypoglycemic effects of Sutherlandia frutescens R. BR. (variety Incana E. MEY.) [Fabaceae] shoot aqueous extract.
Ojewole JA.

Department of Pharmacology, Faculty of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

Previous studies on the pharmacology of South African medicinal plants in our laboratories and elsewhere have shown that some plants possess therapeutic attributes. One such ethnomedically useful plant is Sutherlandia frutescens R. BR. (family: Fabaceae). S. frutescens is widely used in South African traditional medicine for the management and/or control of a plethora of human ailments. In order to scientifically appraise some of the ethnomedical uses of S. frutescens, the present study was undertaken to investigate the analgesic, antiinflammatory and antidiabetic properties of the plant's shoot aqueous extract in experimental animal models. The analgesic effect of the herb's shoot extract was evaluated using the hot-plate and acetic acid test models of pain in mice, while the antiinflammatory and hypoglycemic effects of the plant's shoot aqueous extract were investigated in rats, using fresh egg albumin-induced pedal (paw) edema, and streptozotocin (STZ)-induced diabetes mellitus. Diclofenac (100 mg/kg) and chlorpropamide (250 mg/kg) were used, respectively, as reference drugs for comparison. S. frutescens shoot aqueous extract (50-800 mg/kg i.p.) produced significant (p < 0.05-0.001) analgesic effects against thermally- and chemically-induced nociceptive pain stimuli in mice. The plant extract (50-800 mg/kg p.o. or i.p.) also significantly (p < 0.05-0.001) inhibited fresh egg albumin-induced acute inflammation and caused significant (p < 0.05-0.001) hypoglycemia in rats. The various chemical constituents and secondary metabolites of the herb are speculated to account for the observed analgesic, antiinflammatory and hypoglycemic effects of the plant. The results of this experimental animal study suggest that S. frutescens shoot aqueous extract possesses analgesic, antiinflammatory, and hypoglycemic properties, and thus lend pharmacological credence to the suggested folkloric uses of the herb in the management and/or control of painful, arthritic and other inflammatory conditions, as well as for adult-onset, type-2 diabetes mellitus in some communities of South Africa.


Biofactors. 2004;21(1-4):149-53.

Inhibition of phorbol ester-induced COX-2 expression by some edible African plants.
Na HK, Mossanda KS, Lee JY, Surh YJ.

Laboratory of Biochemistry and Molecular Toxicology, College of Pharmacy, Seoul National University, South Korea.

Cancer bush (CB, Sutherlandia frutescens), Devil's claw (DEV, Harpagophytum procumbens), Rooibos tea (RT, Aspalathus linearis), and Bambara groundnut (BB, Vignea subterranean) have been used to treat some malignancies and inflammatory disorders in Africa. However, biochemical basis for chemopreventive effects of these medicinal plants remains unclear. An abnormally elevated expression of cyclooxygenase-2 (COX-2) has been implicated in pathogenesis and progression of carcinogenesis. In the present study, we found that the methanol extracts of CB, DEV, RT, and BB inhibited, to a different extent, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced COX-2 expression in human breast epithelial (MCF10A) cells and in mouse skin in vivo. To determine the molecular mechanism of COX-2 inhibition by the above medicinal plants, we examined their effects on activation of NF-kappaB which is one of the major transcription factors responsible for regulating COX-2 expression. Methanol extracts of both CB and BB inhibited the DNA binding of NF-kappaB activated by TPA in MCF10A cells in a dose-dependent manner. Based on above findings, CB and BB are likely to inhibit TPA-induced COX-2 expression through suppression of DNA binding of NF-kappaB, which may contribute to the chemopreventive or chemoprotective activity of these African plants


J Ethnopharmacol. 2005 Apr 8;98(1-2):163-70.

Sutherlandia frutescens extracts can induce apoptosis in cultured carcinoma cells.
Chinkwo KA.

Laboratory of Biochemistry, Department of Biotechnology, University of the Western Cape, Private Bag X17, Bellville 7535, Cape Town, South Africa.

Sutherlandia frutescens popularly known as cancer bush is endemic to Southern Africa. Whole plant parts have been used and traditional healers claim that it can treat cancer. In this study it is shown that a crude aqueous Sutherlandia frutescens whole plant extract induced cytotoxicity in neoplastic cells (cervical carcinoma) and CHO (Chinese Hamster Ovary cells) cell lines. Morphological observation and monitoring with other biological assays involving chromatin condensation as well as phosphotidyl serine externalisation point to apoptotic responses. Further biochemical assays showed similar DNA fragmentation patterns induced by Sutherlandia frutescens extracts compared to other inducers of apoptosis such as staurosporine and ceramide. Furthermore, Sutherlandia frutescens extracts induced apoptosis was confirmed by flow cytometric analysis. These findings warrant further research with a view to develop Sutherlandia frutescens extracts for use in anti-cancer therapy.


Endocr Res. 2004 Nov;30(4):745-51.

The effect of Sutherlandia frutescens on steroidogenesis: confirming indigenous wisdom.
Prevoo D, Smith C, Swart P, Swart AC.

Department of Biochemistry, University of Stellenbosch, Stellenbosch, South Africa.

Sutherlandia frutescens (Cancer bush), a Southern African indigenous plant, is traditionally used to treat stress related maladies linked to the endocrine system. Extracts of the shrub were used to investigate the claimed stress-relieving properties of the shrub. Dysregulation of the stress response is associated with elevated glucocorticoid levels. A model of chronic intermittent immobilization stress was investigated in 40 adult male Wistar rats to determine the effect of Sutherlandia. Immobilization stress resulted in increased corticosterone levels in the control group while rats receiving Sutherlandia extract showed significantly decreased corticosterone levels (P < 0.005). Since the biosynthesis of glucocorticoids in the adrenals is catalyzed by the cytochrome P450-dependent enzymes, the influence of Sutherlandia extracts on adrenal steroidogenesis was determined in ovine adrenocortical microsomes and mitochondria, using spectral binding and enzyme conversion assays. Water extracts showed inhibition of substrate binding to cytochrome P450 21-hydroxylase (CYP21) by 38% and cytochrome P450 11beta-hydroxylase (CYP11B1) by 60%. The conversion of progesterone and pregnenolone was inhibited by 34% and 30%, respectively. Subsequent extractions with chloroform and methanol showed inhibition of substrate binding and conversion with hydrophobic compounds exhibiting a greater inhibitory effect on deoxycorticosterone binding to CYP11B1 (30%) and on progesterone binding to CYP21 (50%). The inhibition of binding of pregnenolone to CYP17 by the chloroform extract was 62%, with negligible inhibition by the methanol extract. The chloroform extract showed a greater inhibitory effect than the methanol extract on progesterone and pregnenolone metabolism (20%-50%).


Cancer Lett. 2005 Jan 31;218(1):21-31.

Inhibitory effects of the extracts of Sutherlandia frutescens (L.) R. Br. and Harpagophytum procumbens DC. on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets.
Kundu JK, Mossanda KS, Na HK, Surh YJ.

Laboratory of Biochemistry and Molecular Toxicology, College of Pharmacy, Seoul National University, Shinlim-dong, Kwanak-ku, Seoul 151-742, South Korea.

Numerous anti-nflammatory agents have been shown to exert chemopreventive activity by targeting cyclooxygenase (COX)-2, a rate-limiting enzyme involved in the inflammatory process. Sutherlandia frutescens (L.) R. Br. and Harpagophytum procumbens DC., which are commonly known as Cancer bush (CB) and Devil's claw (DC), respectively, have long been used in South Africa for the management of pain and inflammation. In the present study, we investigated the effects of methanolic extracts of CB and DC on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced COX-2 expression in mouse skin. Topical application of both extracts inhibited TPA-induced COX-2 expression. As an underlying mechanism of COX-2 inhibition, these extracts diminished TPA-stimulated catalytic activity of extracellular signal-regulated protein kinase (ERK), which is known to regulate the activation of eukaryotic transcription factors mediating COX-2 induction. While TPA-induced activation of nuclear factor-kappaB remained unaffected by both extracts, they inhibited TPA-induced activation of activator protein-1 (AP-1) and attenuated the expression of its key component c-Fos. In another study, topical application of TPA induced DNA binding of cyclic AMP response element binding (CREB) protein in mouse skin in vivo, which was abrogated by pretreatment with either CB or DC


AIDS. 2005 Jan 3;19(1):95-97.

Impact of African herbal medicines on antiretroviral metabolism.
Mills E, Foster BC, Heeswijk RV, Phillips E, Wilson K, Leonard B, Kosuge K, Kanfer I.

Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
University of British Columbia, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
Division of Infectious Diseases, Ottawa General Hospital, Ottawa, Ontario, Canada
Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Canadian College of Naturapathic Medicine, Toronto, Ontario, Canada
Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa.

We examined the effects of two African herbal medicines recommended for HIV/AIDS patients on antiretroviral metabolism. Extracts from Hypoxis and Sutherlandia showed significant effects on cytochrome P450 3A4 metabolism and activated the pregnane X receptor approximately twofold. P-glycoprotein expression was inhibited, with Hypoxis showing 42-51% and Sutherlandia showing 19-31% of activity compared with verapamil. Initiating policies to provide herbal medicines with antiretroviral agents may put patients at risk of treatment failure, viral resistance or drug toxicity.


J Ethnopharmacol. 2004 Jul;93(1):9-19.

In vitro culture studies of Sutherlandia frutescens on human tumor cell lines.
Tai J, Cheung S, Chan E, Hasman D.

Departments of Pathology and Pediatrics, Center for Complementary Medicine Research, BC's Research Institute for Children's and Women's Health, University of British Columbia, 4480 Oak Street, Vancouver, BC, Canada V5Z 4H4.

Sutherlandia frutescens is a South African herb used traditionally by the natives to treat cancer, and more recently to improve the overall health in HIV/AIDS patients. Gas chromatography/mass spectrometer profiling and liquid chromatographic/mass spectral investigation confirmed and quantified the presence of canavanine, GABA and arginine in the herbal preparation used in this study. In vitro study demonstrated a concentration dependent effect of Sutherlandia on several tumor cell lines, with 50% inhibition (IC50) of proliferation of MCF7, MDA-MB-468, Jurkat and HL60 cells at 1/250, 1/200, 1/150 and 1/200 dilutions, respectively. Sutherlandia treatment did not induce HL60 differentiation along the macrophage/monocyte or granulocyte lineage. It demonstrated antioxidant activity in reducing free radical cations with an estimated activity of 0.5 microl of Sutherlandia extract equivalent to that of 10 microM of Trolox. However, it did not significantly suppress lipopolysaccharide stimulated nitric oxide production by murine macrophage/monocyte RAW 264.7 cells, nor did it significantly inhibit IL-1beta and TNF-alpha mRNA expression in RAW 264.7 cells. In conclusion, Sutherlandia ethanolic extract showed a concentration dependent antiproliferative effect on several human tumor cell lines but did not show significant antioxidant effects. Further studies are needed to explore the activities of this multipurpose South African herbal preparation.


   


home | chemistry | uses | safety | HIV/AIDS | cancer | MRC Study | CFS
Diabetes | Canavanine | Q&A | literature | sources | contact us | links



All information Copyright © 2011 Sutherlandia.org.
Written permission is required for its duplication in any form.
All medical information is provided for educational purposes only and should not replace the advice of your doctor.